Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Friday morning,Benzinga reports. They currently have a $50.00 price target on the stock.

Several other equities analysts also recently weighed in on DYN. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday. Robert W. Baird assumed coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Piper Sandler decreased their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $48.64.

Dyne Therapeutics Trading Up 3.3 %

Dyne Therapeutics stock opened at $13.61 on Friday. The stock has a 50-day moving average price of $16.98 and a 200 day moving average price of $27.73. Dyne Therapeutics has a 52 week low of $12.87 and a 52 week high of $47.45. The stock has a market cap of $1.39 billion, a PE ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,334 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the sale, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,387 shares of company stock valued at $142,789 over the last quarter. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in Dyne Therapeutics by 0.3% during the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after purchasing an additional 721 shares in the last quarter. KBC Group NV grew its stake in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Dyne Therapeutics in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.